Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 30, 2007

View Archived Issues

New treatments for autoimmune diseases and immunological disorders divulged in recent patents

SVT-40776 increases voiding volume in healthy postmenopausal women

Eculizumab reduces thromboembolism risk in paroxysmal nocturnal hemoglobinuria

Recent OSI and Shanghai Hengrui patents impart new therapeutic agents for cancer

Recent Tecnogen patent describes novel treatment options for arthritis

Recent Roche patents disclose new antidepressant agents

IDEAL extension reveals long-term safety of rivastigmine patch in Alzheimer's disease

In vivo efficacy of BMS-687453, a novel PPARalpha agonist, disclosed by BMS

E.U. approves new formulation of Rebif for relapsing MS

Colorectal cancer target may be discontinued based on unfavorable data with matuzumab

Adolor moving closer to possible lift of FDA clinical hold on alvimopan for POI

FDA accepts Schering-Plough/Merck NDA for loratadine/montelukast tablet

MGI Pharma gains rights to thrombopoietin mimetic from AkaRx

Bronchitol demonstrates efficacy in phase III bronchiectasis trial

Biomira initiates phase I trial of PX-478 in patients with advanced metastatic cancers

HGS completes patient enrollment in phase III Albuferon trial

Once-daily Seroquel XR approved in the Netherlands for schizophrenia

ALS-357 granted FDA orphan drug designation for metastatic melanoma

BioLineRx Inlicenses acute kidney injury treatment

Inflazyme will not exercise option with Helicon to buy back IPL-455903

Enrollment complete for phase III trial of Zingo in adults

PDL BioPharma announces changes to focus on antibody R&D

Fast track status granted to Pharmion's oral azacitidine for MDS

Phase II pediatric clinical evaluation of intravenous artesunate for severe malaria commences

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...